After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).
The patient has iMCD, which has a poor survival rate and few treatment options but an AI tool searched through 4,000 ...
UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
Long-term TNFi use in patients with psoriasis was not associated with a higher risk of cancer, including lymphoma, prostate cancer, and breast cancer.
SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...
Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback